论文部分内容阅读
目的:探讨分析优甲乐联合131碘治疗甲状腺乳头状癌术后的临床疗效。方法:将2012年1月至2013年3月间在我院进行治疗的166例甲状腺乳头状癌患者按照治疗方法分为两组,治疗组于术后给予优甲乐联合131碘治疗,对照组术后只给予优甲乐治疗,比较两组疗效。结果:治疗后,治疗组的总有效率为91.57%,显著对照组的80.72%,具有显著性差异(P<0.05);治疗组的复发率、癌症转移率以及患者死亡率分别为3.61%、6.02%和1.20%,均明显低于对照组的13.25%、15.66%和8.43%,具有显著性差异(P<0.05)。结论:优甲乐联合131碘治疗甲状腺乳头状癌术后的临床疗效显著,可有效降低复发率、癌症转移率以及患者死亡率,值得临床推广应用。
Objective: To investigate the clinical efficacy of Euthyrox and 131 iodine in the treatment of papillary thyroid carcinoma. Methods: One hundred and sixty-six patients with thyroid papillary carcinoma treated in our hospital from January 2012 to March 2013 were divided into two groups according to the method of treatment. The patients in the treatment group were treated with Euthyrox 131I and 131I after the operation, while the control group Euthyrox after treatment was given only to compare the efficacy of the two groups. Results: After treatment, the total effective rate was 91.57% in the treatment group and 80.72% in the significant control group, with significant difference (P <0.05). The recurrence rate, cancer metastasis rate and mortality rate in the treatment group were 3.61% 6.02% and 1.20%, respectively, were significantly lower than the control group 13.25%, 15.66% and 8.43%, with significant differences (P <0.05). Conclusion: Euthyrox and 131 iodine is effective in treating papillary thyroid carcinoma after thyroidectomy, which can effectively reduce the recurrence rate, cancer metastasis rate and mortality rate, which is worthy of clinical application.